Our AI-based approach is designed to:
- Enhance R&D efficiencies
- Shorten development timelines
- Increase probability of success
Mar 27, 2025
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024VIEW RELEASE
Mar 11, 2025
BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaVIEW RELEASE
Mar 07, 2025
BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaVIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Apr 24, 2025 04:00 PM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
1.85
CHANGE
0.16 (9.47%)
